Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 42

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 3
Chunk 42
---
 circumstances.

The maximum indemnification amount set forth in such agreements
is limited to an amount equal to 25% of our shareholders’ equity as reflected in our most recent consolidated financial statements
prior to the date on which the indemnity payment is made. If the amount equal to 25% of our shareholders’ equity is insufficient
to cover all indemnity amounts payable with respect to all indemnifiable directors and executive officers, such amount will be allocated
among our directors and executive officers pro rata, in accordance with their relative culpabilities, as finally determined by a court
with respect to a particular claim. The maximum amount set forth in such agreements is in addition to any amount paid (if paid) under
insurance and/or by a third party pursuant to an indemnification arrangement. In the opinion of the SEC, indemnification of directors
and office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable.

93

D. Employees

The total number of employees in Evogene and its subsidiaries as
of December 31, 2022,2023 and 2024 was 137,142 and 117 respectively. As of December 31, 2024, our research and development activities
involved 75 employees amounting to approximately 64% of our total full-time workforce, of which 36 were employed by Evogene and 39 were
employed by our subsidiaries. In 2024, our employees included individuals with degrees in biology, chemistry, plant genetics, agronomics,
computer and data science and other related fields and 36 of our employees hold a Ph. D. As of March 20, 2025, the total number of employees
in Evogene and its subsidiaries was 106.

The rate of male v. female in our company and our main subsidiaries
as of December 31, 2024, was as follows:

  Company                             
 ──────────────────────────────────────
  Evogene        56      44       66  
  AgPlenus       55      45       11  
  Lavie Bio      47      53       17  
  Biomica        67      33       18  
  Casterra       20      80        5  
  Total          49      51      117  

The rate of male v. female in a managing position (i. e., any such
person that oversees and supervises other employees) in our company and our subsidiaries